DK3371179T3 - Hidtil ukendte cryptophycin-forbindelser og konjugater, deres fremstilling og terapeutisk anvendelse heraf - Google Patents

Hidtil ukendte cryptophycin-forbindelser og konjugater, deres fremstilling og terapeutisk anvendelse heraf Download PDF

Info

Publication number
DK3371179T3
DK3371179T3 DK16791017T DK16791017T DK3371179T3 DK 3371179 T3 DK3371179 T3 DK 3371179T3 DK 16791017 T DK16791017 T DK 16791017T DK 16791017 T DK16791017 T DK 16791017T DK 3371179 T3 DK3371179 T3 DK 3371179T3
Authority
DK
Denmark
Prior art keywords
conjugates
unknown
preparation
therapeutic application
cryptophycin compounds
Prior art date
Application number
DK16791017T
Other languages
Danish (da)
English (en)
Inventor
Antony Bigot
Hervé Bouchard
Marie-Priscille Brun
François Clerc
Jidong Zhang
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK3371179T3 publication Critical patent/DK3371179T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Bedding Items (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16791017T 2015-11-05 2016-11-03 Hidtil ukendte cryptophycin-forbindelser og konjugater, deres fremstilling og terapeutisk anvendelse heraf DK3371179T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (en) 2015-11-05 2016-11-03 Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
DK3371179T3 true DK3371179T3 (da) 2019-11-11

Family

ID=54476881

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16791017T DK3371179T3 (da) 2015-11-05 2016-11-03 Hidtil ukendte cryptophycin-forbindelser og konjugater, deres fremstilling og terapeutisk anvendelse heraf

Country Status (36)

Country Link
US (2) US10941139B2 (enExample)
EP (1) EP3371179B1 (enExample)
JP (1) JP6929292B2 (enExample)
KR (1) KR102822076B1 (enExample)
CN (1) CN108349960B (enExample)
AR (1) AR106604A1 (enExample)
AU (1) AU2016347724B2 (enExample)
CA (1) CA3003085A1 (enExample)
CL (1) CL2018001210A1 (enExample)
CO (1) CO2018004581A2 (enExample)
CR (1) CR20180256A (enExample)
CY (1) CY1122441T1 (enExample)
DK (1) DK3371179T3 (enExample)
EA (1) EA035625B1 (enExample)
EC (1) ECSP18034035A (enExample)
ES (1) ES2755101T3 (enExample)
HK (1) HK1256754B (enExample)
HR (1) HRP20191729T1 (enExample)
HU (1) HUE046033T2 (enExample)
IL (1) IL259067B (enExample)
LT (1) LT3371179T (enExample)
MA (1) MA43160B1 (enExample)
MX (1) MX374535B (enExample)
MY (1) MY189448A (enExample)
PE (1) PE20181619A1 (enExample)
PH (1) PH12018500852B1 (enExample)
PL (1) PL3371179T3 (enExample)
PT (1) PT3371179T (enExample)
RS (1) RS59498B1 (enExample)
SG (1) SG11201803181SA (enExample)
SI (1) SI3371179T1 (enExample)
TN (1) TN2018000131A1 (enExample)
TW (1) TWI714661B (enExample)
UY (1) UY36979A (enExample)
WO (1) WO2017076998A1 (enExample)
ZA (1) ZA201802322B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
WO2018206635A1 (en) * 2017-05-10 2018-11-15 Sanofi Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
CN108107103B (zh) * 2017-12-14 2020-10-16 华中师范大学 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法
AU2020231396B2 (en) 2019-03-07 2025-03-20 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
US11530204B2 (en) 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
EP4495105A1 (en) 2023-07-17 2025-01-22 Basf Se 3-(4-hydroxybut-2-ynoxy)propanoic acid ester, amide and nitrile derivatives as corrosion protection agents
EP4495108A1 (en) 2023-07-17 2025-01-22 Basf Se 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy]propanoic acid derivatives as precursors of monomers in polymerisations
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203016T1 (de) * 1993-12-21 2001-07-15 Univ Hawaii Cryptophycine
US20020128185A1 (en) * 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途

Also Published As

Publication number Publication date
AU2016347724A1 (en) 2018-05-10
CO2018004581A2 (es) 2018-07-19
PE20181619A1 (es) 2018-10-11
WO2017076998A1 (en) 2017-05-11
ECSP18034035A (es) 2018-05-31
RS59498B1 (sr) 2019-12-31
HUE046033T2 (hu) 2020-01-28
US20190382391A1 (en) 2019-12-19
CY1122441T1 (el) 2021-01-27
PH12018500852B1 (en) 2021-08-11
CN108349960A (zh) 2018-07-31
HRP20191729T1 (hr) 2019-12-13
ES2755101T3 (es) 2020-04-21
EA201890898A1 (ru) 2018-10-31
CN108349960B (zh) 2022-05-27
JP6929292B2 (ja) 2021-09-01
SG11201803181SA (en) 2018-05-30
SI3371179T1 (sl) 2019-11-29
EP3371179A1 (en) 2018-09-12
TWI714661B (zh) 2021-01-01
MX2018005379A (es) 2018-09-05
CL2018001210A1 (es) 2018-08-17
MX374535B (es) 2025-03-06
CR20180256A (es) 2018-08-13
AU2016347724B2 (en) 2021-04-01
MA43160B1 (fr) 2019-12-31
UY36979A (es) 2017-06-30
PH12018500852A1 (en) 2018-10-29
JP2018535255A (ja) 2018-11-29
LT3371179T (lt) 2019-11-11
BR112018008490A2 (pt) 2019-02-12
NZ741734A (en) 2023-10-27
PT3371179T (pt) 2019-11-18
US20210163458A1 (en) 2021-06-03
EP3371179B1 (en) 2019-08-07
IL259067A (en) 2018-06-28
TW201730164A (zh) 2017-09-01
PL3371179T3 (pl) 2020-02-28
KR102822076B1 (ko) 2025-06-18
MY189448A (en) 2022-02-14
CA3003085A1 (en) 2017-05-11
ZA201802322B (en) 2019-01-30
KR20180073678A (ko) 2018-07-02
IL259067B (en) 2021-07-29
US10941139B2 (en) 2021-03-09
TN2018000131A1 (en) 2019-10-04
EA035625B1 (ru) 2020-07-17
AR106604A1 (es) 2018-01-31
HK1256754B (en) 2020-06-05

Similar Documents

Publication Publication Date Title
IL290823A (en) Pharmaceutical compositions for combination therapy
DK4234581T3 (da) Terapeutiske antistoffer og deres anvendelse
IL256652A (en) Therapeutic compositions, combinations, and methods of use
IL258931A (en) Therapeutic compounds and methods
EP3463464A4 (en) ASSOCIATION TREATMENT
EP3522966A4 (en) PATIENT INTERFACES
EP3349796A4 (en) THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
EP3513809A4 (en) MEDICAL COMPOSITION
EP3291824C0 (en) ANTIMICROBIAL THERAPY
IL268648B (en) Therapeutic dendrimers
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
IL254251A0 (en) Human fibrolamellar hepatocellular carcinomas (hfl-hccs)
HUE046033T2 (hu) Új kriptoficin vegyületek és konjugátumok, elõállításuk és gyógyászati alkalmazásuk
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
IL260347A (en) Therapeutic anti-cd9 antibody
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
IL262929A (en) Composition, and application and pharmaceutical preparation thereof
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
IL253549B (en) Antibody-urease conjugates for therapeutic purposes
DK3408265T3 (da) Terapeutiske forbindelser
IL262851A (en) Combination prime: boost therapy